The company has laid out the R&D pipeline of several new drug. It has developed the latest international thrombolytic drug rhTNK-tPA, which fills the gap in China. An advanced platform for continuous serum-free culture of large-scale animal cells has been established, breaking through the technical bottleneck of the industry, which can be applied to the research on vaccines, stem cells, gene therapy, cell therapy, and other fields in the future.
R&D capability
The company views independent innovation capability as a top priority, and has undertaken 37 projects including the Significant New Drugs Creation Project of 10th Five-Year plan, the National Development and Reform Commission’s Strategic Emerging Industry Project, and science and technology projects in districts,city and provincial levels . The R&D achievements have been granted by 11 patents, including 7 invention patents, and won 1 China Patent Excellence Award. These achievements have provided strong scientific and technological support for the company to explore the market and increase its core competitiveness.
projects
37including 5 national projects
patents
11 including 7 invention patentsR&D achievements
-
Recombinant human TNK tissue-type plasminogen activator rhTNK-tPA for injection
rhTNK-tPA
-
Recombinant humanized anti-EGFR monoclonal antibody rhuMAb EGFR
rhuMAb EGFR
-
Recombinant hirudin (yeast-secreted) rHirudin for injection
rHirudin
-
Recombinant (yeast-secreted) human granulocyte-macrophage colony-stimulating factor rhGM-CSF for injection
rhGM-CSF